Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Transplant Cell Ther. 2020 Sep 19;27(1):58–66. doi: 10.1016/j.bbmt.2020.09.014

Figure 1:

Figure 1:

Adjusted transplantation outcomes of DLBCL patients receiving RIC regimens. A) Cumulative incidence of chronic graft-versus-host-disease. B) Cumulative incidence of non-relapse mortality. C) Cumulative incidence of lymphoma relapse/progression. D) Progression-free survival. E) Overall survival